lasofoxifene vs fulvestrant for locally advanced/metastatic er /her2- breast cancer: elaine trial
Published 1 year ago • 169 plays • Length 4:34Download video MP4
Download video MP3
Similar videos
-
2:35
lasofoxifene shows promise for women with esr1-mutated mbc
-
5:47
elaine 1: las vs fulv in la er /her2- mbc esr1m disease progression on ai and cdk4/6i inhibitors
-
2:06
elaine 1: esr1 mutations in ctdna from er /her2- mbc treated with lasofoxifene or fulvestrant
-
6:55
mafalda oliveira, sabcs 2022: camizestrant vs fulvestrant for advanced er her2- breast cancer
-
4:11
inavo, palbo plus fulv sees sustained benefit beyond disease progression in her2‑negative locall...
-
4:15
lasofoxifene vs fulvestrant for hr-positive breast cancer
-
5:24
fulvestrant– faslodex®
-
34:06
the emerging role of serd's in hr breast cancer
-
20:37
gs2-02: "elacestrant, an oral selective estrogen receptor degrader (serd), vs investigator’s..."
-
13:09
get all the info you need about her2 ve breast cancer - her2 ve breast cancer || dr liz o'riordan
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
4:05
camizestrant may be superior to fulvestrant in patients with hr-positive, her2-negative bc
-
5:34
monarch 2: overall survival of abemaciclib plus fulvestrant in hr , her2- advanced breast cancer
-
1:54
her2 positive metastatic breast cancer treatment options explained
-
1:56
vepdegestrant palbociclib in er metastatic breast cancer: phase ib trial results
-
5:28
comment: fulvestrant improves survival over anastrozole for patients with advanced breast cancer
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
6:55
fulvestrant versus anastrozole in patients with advanced breast cancer
-
7:27
introduction and exploration of fulvestrant in metastatic breast cancer
-
1:02
phase iii trial of pf-07220060 and fulvestrant in hr /her2- breast cancer